Literature DB >> 1867627

Time-dependent effects of post-trial amphetamine treatment in rats: evidence for enhanced storage of representational memory.

B J Strupp1, M Bunsey, D Levitsky, M Kesler.   

Abstract

Two studies were conducted to test the ability of post-trial amphetamine treatment to improve later recall in a nonaversively motivated task. These studies utilized 8- and 12-arm radial mazes, respectively, with an 11-h retention interval imposed after the rat traversed half the arms of the maze (termed, the to-be-remembered-event, or TBRE). In Experiment 1, the rats were injected with amphetamine (0, .25, and .50 mg/kg) immediately after the TBRE. Because the drug treatment improved retention, a time dependency study was conducted in which the drug (0 and .33 mg/kg) was administered 0, 3, and 6 h after the TBRE. The finding that amphetamine injection at 0, but not 3, h post-trial improved later recall indicates that the benefit derived from the former treatment is not due to proactive influences at the time of the retention test. Drug treatment 6 h post-trial produced a borderline improvement of recall; possible mechanisms are discussed. Two conclusions can be drawn from these results: (1) amphetamine administration can improve recall under conditions in which this effect cannot be attributed to alterations in information processing during either the learning or the retention sessions, indicating that the drug modulates memory storage processes; and (2) amphetamine treatment can improve working memory, thus excluding an alternative interpretation for the previous reports of impaired short-term memory in animals, all of which entailed assessments of working memory. The possibility remains, however, that the impairment seen in these tasks reflects the requirement for erasure of information from previous trials within each daily session, rather than the duration of the retention interval.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867627     DOI: 10.1016/0163-1047(91)90291-w

Source DB:  PubMed          Journal:  Behav Neural Biol        ISSN: 0163-1047


  8 in total

1.  Post-training, but not post-reactivation, administration of amphetamine and anisomycin modulates Pavlovian conditioned approach.

Authors:  Cory A Blaiss; Patricia H Janak
Journal:  Neurobiol Learn Mem       Date:  2007-01-26       Impact factor: 2.877

2.  Cognitive effects of milacemide and methylphenidate in healthy young adults.

Authors:  J A Camp-Bruno; R L Herting
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

3.  A rat model of distractibility: effects of drugs modifying dopaminergic, noradrenergic and GABAergic neurotransmission.

Authors:  A Agmo; C Belzung; C Rodríguez
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Adrenocortical suppression blocks the memory-enhancing effects of amphetamine and epinephrine.

Authors:  B Roozendaal; O Carmi; J L McGaugh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

5.  Combined effects of acute stress and amphetamine on serial memory retrieval pattern in mice.

Authors:  Christophe Piérard; Christophe Tronche; Pierrette Liscia; Frédéric Chauveau; Daniel Béracochéa
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

6.  Motor and cognitive functions of the neostriatum during bilateral blockade of its dopamine receptors.

Authors:  K B Shapovalova; Yu V Kamkina
Journal:  Neurosci Behav Physiol       Date:  2008-01

7.  Mephedrone and nicotine: oxidative stress and behavioral interactions in animal models.

Authors:  Barbara Budzynska; Anna Boguszewska-Czubara; Marta Kruk-Slomka; Jacek Kurzepa; Grazyna Biala
Journal:  Neurochem Res       Date:  2015-04-11       Impact factor: 3.996

Review 8.  Effects of drugs of abuse on hippocampal plasticity and hippocampus-dependent learning and memory: contributions to development and maintenance of addiction.

Authors:  Munir Gunes Kutlu; Thomas J Gould
Journal:  Learn Mem       Date:  2016-09-15       Impact factor: 2.460

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.